Snowdon V K, Guha N, Fallowfield J A
MRC/Centre for Inflammation Research, QMRI, University of Edinburgh, Edinburgh EH16 4TJ, UK.
Int J Hepatol. 2012;2012:691089. doi: 10.1155/2012/691089. Epub 2012 Jun 7.
Portal hypertension is the main cause of complications in patients with cirrhosis. However, evaluating the development and progression of portal hypertension represents a challenge for clinicians. There has been considerable focus on the potential role of noninvasive markers of portal hypertension that could be used to stratify patients with respect to the stage of portal hypertension and to monitor disease progression or treatment response in a longitudinal manner without having to undertake repeated invasive assessment. The pathogenesis of portal hypertension is increasingly understood and emerging knowledge of the vascular processes that underpin portal hypertension has paved the way for exploring novel biomarkers of vascular injury, angiogenesis, and endothelial dysfunction. In this paper we focus on the pathogenesis of portal hypertension and potential non-invasive biomarkers with particular emphasis on serum analytes.
门静脉高压是肝硬化患者并发症的主要原因。然而，评估门静脉高压的发生和进展对临床医生来说是一项挑战。人们相当关注门静脉高压非侵入性标志物的潜在作用，这些标志物可用于根据门静脉高压阶段对患者进行分层，并纵向监测疾病进展或治疗反应，而无需进行重复的侵入性评估。门静脉高压的发病机制越来越为人所理解，对支撑门静脉高压的血管过程的新认识为探索血管损伤、血管生成和内皮功能障碍的新型生物标志物铺平了道路。在本文中，我们重点关注门静脉高压的发病机制和潜在的非侵入性生物标志物，尤其着重于血清分析物。
